Looking Forward: Section 337 Investigations as Big Pharma's New Enforcer
- Christopher M. Gallo
- Sterne, Kessler, Goldstein & Fox
In this article, Christopher M. Gallo discusses the increase of generic pharmaceutical competition under the Hatch-Waxman Act and the growing number of innovator companies that are utilizing ITC Section 337 investigations to curb generic competition and maintain market exclusivity. To access the full article, click on the PDF above.
Article originally published in Vol. XXXIV 337 Rep., ITC Trial Law. Ass'n, The Paul J. Luckern Summer Associate Edition 2 (2011).